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Cancer Cell
Previewslarger number of patients whose tumors
harbor potentially druggable alterations
sparks hope for a more positive outlook
on patient outcomes in the near future.
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Pre B-ALL is an aggressive cancer of the blood for which treatment of patients with relapsed and refractory
disease remains a challenge. In this issue ofCancer Cell, Geng and colleagues surveyed the activation status
of the pre-B cell receptor and comprehensively investigated downstream signaling mechanisms currently
targetable with small molecule inhibitors.Pre-B cell acute lymphoblastic leukemia
(pre B-ALL) is an aggressive hemato-
logical malignancy that is the result
of oncogenic transformation of an early
B-lymphocyte progenitor. It is the most
common form of pediatric cancer.
Despite tremendous advances in the
treatment of this disease over the last
decades, including recent breakthroughs
in the area of immunotherapy (Grupp
et al., 2013), there remain patients who
experience relapsed disease for which
the prognosis is dismal (Bhatla et al.,
2014). Therefore, development of thera-
peutic strategies that target the specific
mechanisms that contribute to the onco-
genic state are of great interest, because
these may offer options for those who
are untreatable with current protocolsand possibly a more effective alternative
even for those who do respond to stan-
dard therapy.
In this issue of Cancer Cell, Geng et al.
(2015) have taken an important key step
toward that goal. Building on previous
studies that clearly demonstrated the
importance of signaling through the pre-
B cell receptor (pre-BCR) for B-lympho-
cyte survival during normal development
(Hess et al., 2001), the authors aimed to
clarify if a similar mode of signaling might
represent a targetable susceptibility in
pre-B-ALL (Geng et al., 2015). There is
precedent for this hypothesis, because
studies in more phenotypically mature
B cell malignancies, such as chronic
lymphocytic leukemia, diffuse large B cell
lymphoma, andmantle cell lymphoma, re-vealed a critical role for B cell receptor
(BCR) signaling in disease pathogenesis
(Byrd et al., 2013; Davis et al., 2010;
Wang et al., 2013). These studies have
described two distinct modes of BCR
signaling. Tonic BCR signaling has been
shown to be important for the survival of
normal B cells as well as tumor cells and
acts primarily through SRC and SYK ki-
nases (Juszczynski et al., 2009), while
chronic-activated BCR signaling engages
multiple downstream signaling cascades,
including NF-kB and BTK (Davis et al.,
2010). This information has led to
significant translational breakthroughs,
because inhibitors of both of these
signaling mechanisms have been devel-
oped (Young and Staudt, 2013). There-
fore, the realization of a similar route of27, March 9, 2015 ª2015 Elsevier Inc. 321
Figure 1. Mechanism of Pre-BCR Gene Induction and Specific
Vulnerabilities of TCF3-PBX1 B-ALL
As detailed by Geng et al. (2015), the TCF3-PBX1 gene fusion product directly
controls activation of components of the pre-BCR. Subsequent signaling
leads to upregulation of BCL6, which also binds regulatory elements of pre-
BCR components (dashed line represents the unclear mechanism by which
BCL6may promote gene activity). Pre-BCR+ tumors were selectively sensitive
to small molecules targeting downstream kinases LYN, SYK, PI3Kd, and BTK.
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Previewstherapeutic intervention in
B-ALL could lead to rapid
improvements in patient
care and possibly improved
outcomes.
The study by Geng et al.
(2015) represents an excel-
lent example of cutting-edge
translational approaches to-
ward understanding funda-
mentally important basic
biology. By taking a bottom-
up approach, the group
hoped to clarify whether pre-
BCR signaling was active in
pre-B-ALL, and, if so, at
what frequency. Finally, the
authors reasoned that if this
were the case, it may repre-
sent a potentially effective
avenue for therapy in B-ALL.
The authors began their study
by surveying surface expres-
sion of components of the
pre-BCR on a panel of pri-
mary B-ALL xenografts andcell lines. These results indicated a poten-
tial subset of cases that were positive for
these proteins, leading the authors to
probe for activity of pre-BCR signaling in
a large cohort of patient samples. Using
both surface marker expression and pro-
tein arrays, a subset of patient samples
showing evidence of assembly of the
pre-BCR and engagement of tonic
signaling were identified. Using expres-
sion of the pre-BCR components and
downstream kinases SYK and ZAP70 as
surrogates for pathway activation, Geng
et al. (2015) discovered that a gene fusion
between transcription factors TCF3 and
PBX1 was a frequent genetic event within
the pre-BCR+ patient subset. This led the
authors to further investigate whether the
product of this gene fusion might directly
control expression of genes involved in
pre-BCR signaling by using chromatin
immunoprecipitation followed by high-
throughput sequencing (ChIP-seq). These
studies revealed that the TCF3-PBX1
fusion directly binds and activates com-
ponents of the pre-BCR in B-ALL,
providing a mechanistic link between
the genetics and phenotypes of this sub-
set (Figure 1). The authors went a step
further and used a mouse model of
B-ALL driven by a TCF3-PBX1 transgene
to show that these tumors also utilize
pre-BCR signaling, whereas models322 Cancer Cell 27, March 9, 2015 ª2015 Elsdriven by BCR-ABL1 or MLL-AF4 fusions
did not.
Geng et al. (2015) noticed that high
expression of the transcription factor
BCL6 was another defining feature of
pre-BCR+ B-ALL samples, and, due to
its key role in normal B cell development,
they hypothesized that it might be impor-
tant in this subset of patients. While they
did not observe any evidence of direct
transcriptional regulation of BCL6 by
TCF3-PBX1, they clearly showed that
its expression was induced following in-
duction of pre-BCR signaling. Addition-
ally, they demonstrated that high BCL6
protein expression is nearly obligatory
in cases with surface expression of the
pre-BCR. In support of previous findings,
they observed a reduction in BCL6 pro-
tein following small molecule inhibition
of SYK and BTK, again reinforcing the
association between pre-BCR signaling
and induction of that gene. These results
suggest that BCL6 expression could
perhaps be used as a biomarker to iden-
tify patients with the pre-BCR+ pheno-
type. The authors went on to show that
inhibition or deletion of BCL6 in pre-
BCR+ B-ALL let to tumor regression us-
ing mouse models as well as xenografts
of human tumor material, suggesting its
potential as a therapeutic target in this
disease.evier Inc.Having clearly characterized
the key features of pre-BCR+
B-ALL, Geng et al. (2015)
turned their attention toward
the investigation of the poten-
tial clinical utility of a panel of
small molecule kinase inhibi-
tors, which might be especially
active against tumors of this
phenotype. Using in vitro as-
says, the authors revealed
enhanced sensitivity of pre-
BCR+ samples to small mole-
cules targeting SYK, PI3Kd,
and SRC family kinases (Fig-
ure 1). In contrast, pre-BCR
cases showed sensitivity to
inhibitors of MEK and ERK,
highlighting differential sig-
naling mechanisms used by
these tumor subsets. In order
to study the potential thera-
peutic benefit of these com-
pounds in an in vivo setting,
the authors used an intrave-
nous xenotransplantation ap-proachusinghumanpre-BCR+ tumorsam-
ples. Overall, dasatinib, a molecule with
inhibitory activity against both ABL1 and
SRC kinases, showed strong antitumor ef-
fects both in vivo and in vitro, with selec-
tively high potency in pre-BCR+ cases.
This finding is of particular importance,
because dasatinib has received approval
from the Food and Drug Administration
(FDA) for treatment of chronic myeloid leu-
kemia (Talpaz et al., 2006) and therefore
may present an accessible treatment alter-
native for pre-BCR+ B-ALL patients.
Overall, the work by Geng et al. (2015)
represents an important new step forward
in identification of a subset of B-ALL pa-
tients that could potentially benefit from
treatment with drugs that have already
secured approval for other indications.
By understanding the specific survival
mechanisms utilized by pre-BCR+ B-ALL
patients, the authors have contributed to
a recent trend in cancer biology, which
has focused on illuminating groups of
patients likely to benefit from therapeu-
tics that have already been tested in the
clinic (Roberts et al., 2014). Ultimately,
this approach could be an efficient
route by which basic cancer research
can impact patient care, which, together
with development of novel therapeutics,
will lead to transformative breakthroughs
going forward.
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There is a pressing need to develop novel, mechanism-based therapeutic approaches that can be used to
improve therapies for genetically defined tumor subtypes. Chan and colleagues have demonstrated recently
that BCL-2 inhibitors can target IDH1/2mutant cancers through a mutant-specific dependency in metabolic
regulation.Our increasing knowledge of the somatic
cancer genome has led to the develop-
ment of molecularly targeted therapies
for an ever-expanding list of cancer sub-
types. This has included the development
of tyrosine kinase inhibitors for hemato-
logic and epithelial tumors, which have
had a substantive clinical impact. How-
ever, there has been an increasing
interest in the development of genotype-
specific targeted therapies that do not
target mutated proteins themselves, but
rather leverage mutant-specific depen-
dencies in a specific genomic context.
In a recent issue of Nature Medicine,
Chan et al. (2015) elucidate a critical
role of IDH1/2 mutations in deregulating
mitochondrial function with therapeutic
implications and suggest that BCL-2
inhibitors can target IDH1/2 mutant
cancers.Isocitrate dehydrogenases (IDHs) cata-
lyze the oxidative decarboxylation of
isocitrate to a-ketoglutarate (a-KG) and
NADPH during the citric acid cycle. Muta-
tions in IDH1 were first identified through
exome sequencing in colorectal cancer
(Sjo¨blom et al., 2006). Shortly thereafter,
recurrent IDH1 and IDH2 mutations were
found in glioma and acute myeloid leuke-
mia (AML) (McKenney and Levine, 2013).
The most common IDH1 and IDH2 muta-
tions in AML affect arginine residues,
R132 of IDH1 protein, or R140 and R172
of IDH2. Of note, metabolomics and
biochemical studies have shown that
the mutant enzymes gain a neomorphic
activity that catalyzes the conversion
of a-KG to (R)-2-hydroxyglutarate [(R)-
2HG]. (R)-2HG may act as an onco-
metabolite by inhibiting the function
of a-KG-dependent enzymes, includingTET family enzymes, Jumonji-C domain
containing proteins, and other critical reg-
ulators of the epigenetic state (Xu et al.,
2011). As a consequence, these muta-
tions can result in dysregulated angiogen-
esis, alterations in the pattern of histone
modifications, and aberrant DNA methyl-
ation (Krell et al., 2013).
In addition to their impact on the epige-
netic state, several studies have sug-
gested that IDH1/2 mutations can alter
global cellular metabolism and that
these alterations in metabolic milieu can
contribute to oncogenic transformation.
Reitman and Yan (2010) noted depletion
of the tricarboxylic acid (TCA) cycle
metabolites citrate, cis-aconitate, a-KG,
malate, and fumarate and an accumu-
lation of biosynthetic precursors in cell
lines that expressed IDH1 R132H and
IDH2 R172K mutations, suggesting that27, March 9, 2015 ª2015 Elsevier Inc. 323
